Repligen Acquires BioLife Solutions for $1.5 Billion to Strengthen Cell and Gene Therapy Leadership

Repligen to acquire BioLife Solutions in a $1.5B cash-and-stock deal to strengthen its position in the fast-growing cell and gene therapy market. Expected to close Q4 2026.